Total Funding
49
72
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3669
Abivax develops medicines that alter the body's natural immune system mechanisms.
- Ana Sharma: Vice President, Global Head of Quality Assurance
- Patrick Malloy: Senior Vice President, Investor RelationsPast Role: VectivBio, Senior Vice President, Investor Relations & Strategic Communications
About the Company
Abivax is a clinical-stage biotechnology company, that mobilizes the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Their aim is to use Abivax's drug development platforms to provide novel and effective treatments to patients with large unmet needs in these therapeutic areas.
